Blinatumomab
2016-0792
Phase 2 mab active
Quick answer
Blinatumomab for Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive is a Phase 2 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Phase
- Phase 2
- Modality
- mab
- Status
- active